Global API Market Analysis

The production of products related to Active Pharmaceutical Ingredients (APIs), in the form of small chemical entities, has been inevitable for the global healthcare industry from the very beginning. The production landscape in the APIs industry has been full of challenges and numerous opportunities owing to the expanding global markets and rapidly evolving social, economic, regulatory, and environmental expectations.

As per our report “Global API Market Analysis”, the global APIs market was anticipated to grow at a CAGR of around 8% during 2005 - 2010. The major factors fueling growth in the industry includes rising number of blockbuster drugs expirations resulting in the growth of generics, rapid drug discovery & development process, increasing demand for contract manufacturing, reduction in manufacturing costs, and a stupendous rise in the pharmaceutical market.

At the regional level, the US is the largest APIs consumer globally, while China is attributed to be the largest APIs producers in the world. However, it is believed that, the BRIC countries will emerge as nations with fastest growing demand for APIs during the next 4-5 years, spurred by increasing living standards in these countries. Additionally, among the therapeutic classes, APIs for cardiovascular diseases, antiulcerants & anti cancer will hold the major share in the global APIs market during the coming years.

Our study indicates that, the basis of delineation in the global APIs industry has shifted from cost to building relationships during the past few years. In a spree to increase process efficiency, APIs companies are focusing on the designing of reactor & product, technology for purification and separation, and wider use of catalysis.

“Global API Market Analysis”, analyzes the global APIs industry by segmenting it into biotech, synthetic, branded, and generics APIs. Each of these segments have been thoroughly studied and analyzed in the report. Separate sections on therapeutic-wise analysis & emerging opportunities from High Potency APIs has also been covered separately in the report. Moreover, the report provides an overview of the industry challenges & regulatory environment, which will help clients in identifying the future demand scenario.

The research contains exhaustive information regarding the market players, recent developments, and geographical markets that will help clients in formulating market strategies and assess opportunity areas in the global APIs market.
[Studien Infos ausblenden]

1. Analyst View
2. Research Methodology
3. APIs - An Introduction
4. Industry Performance
4.1 Market Size and Growth
4.2 Market Segments
4.2.1 Branded & Generics APIs
4.2.2 Synthetic & Biotech APIs
4.3 Future Prospects
5. Analysis by Therapeutic Segments
5.1 Central Nervous System Disorders
5.2 Cardiovascular Diseases
5.3 Diabetes
5.4 Respiratory Disorders
5.5 Oncology
6. Key Geographical Markets
6.1 China
6.2 Italy
6.3 India
7. High-Potency APIs: An Emerging Opportunity
8. Regulatory Environment
9. Industry Restraints
10. Recent Developments
11. Key Players Profile
11.1 Cambrex Corporation
11.2 Daiichi Fine Chemicals
11.3 Dr Reddy’s Laboratories
11.4 Royal DSM
11.5 Lonza
11.6 Matrix Laboratories
11.7 Pfizer CentreSource
11.8 Ranbaxy Laboratories
11.9 Teva Active Pharmaceutical Ingredients

List of Figures:

Figure 4-1: Global - APIs Market (Billion US$), 2005 & 2010
Figure 4-2: Global - Share of Branded & Generics APIs (2010)
Figure 4-3: Global - Share of Synthetic & Biotech APIs (2010)
Figure 6-1: China - APIs Market (Billion US$), 2005 & 2010
Figure 6-2: Italy - APIs Market (Billion US$), 2005 & 2010
Figure 6-3: India - APIs Market (Billion US$), 2005 & 2010
Figure 7-1: Global - Share of HPAPIs in APIs Market (2009)
Figure 7-2: Global - HPAPIs Market by Synthesis Route (%), 2009
Figure 7-3: Global - Share of Generics & Branded in HPAPIs Market (2009)

List of Tables:

Table 3-1: Classification of Bulk Drugs
Table 4-1: Global - Share of Top 10 APIs by Therapeutic Class
[Inhaltsverzeichnis ausblenden]